{"id":300073,"date":"2026-10-09T18:19:07","date_gmt":"2026-10-09T12:49:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=300073"},"modified":"2026-10-09T18:19:07","modified_gmt":"2026-10-09T12:49:07","slug":"neuland-laboratories-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/","title":{"rendered":"Neuland Laboratories Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Neuland Laboratories share price Rs 20,890.00 (9 October 2026). Base target Rs 23,143, bull Rs 28,063, downside risk Rs 16,811. PE 54.16. 52W range Rs 11,500.00 to Rs 24,225.00.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Neuland Laboratories share price target for 2027 is Rs 23,143, about 10.8% above the current price of Rs 20,890.00. The bull case is Rs 28,063, and the downside risk level, which is not a target, is Rs 16,811. The base case assumes earnings per share grow 10.1% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 54.16. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Neuland Laboratories target price for 2027 should start with where the stock sits today. At Rs 20,890.00 on 9 October 2026, it is 13.8% below its 52-week high of Rs 24,225.00 and 81.7% above its 52-week low of Rs 11,500.00. That range spans 111% from low to high, so the entry point matters as much as the Neuland Laboratories price forecast itself.<\/p>\n<p>This article builds the Neuland Laboratories share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 23,143 base case and the Rs 28,063 bull case were reached, along with a downside risk level of Rs 16,811.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=neuland-laboratories-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Neuland_Laboratories_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Neuland Laboratories Stock Analysis: Company Overview and Key Stats\">Neuland Laboratories Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Why_Is_Neuland_Laboratories_Share_Price_Target_Set_at_Rs_23143_for_2027\" title=\"Why Is Neuland Laboratories Share Price Target Set at Rs 23,143 for 2027?\">Why Is Neuland Laboratories Share Price Target Set at Rs 23,143 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Earnings_Growth_Behind_the_Neuland_Laboratories_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Neuland Laboratories Target Price: Five Years of Results\">Earnings Growth Behind the Neuland Laboratories Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Valuation_Check_for_the_Neuland_Laboratories_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Neuland Laboratories Stock Target: PE, Price to Book and ROE\">Valuation Check for the Neuland Laboratories Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Neuland_Laboratories_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Neuland Laboratories Share Price Targets for the Short Term and 12 Months\">Neuland Laboratories Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Short_Term_Neuland_Laboratories_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Neuland Laboratories Stock Target Levels: Technical Setup\">Short Term Neuland Laboratories Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#12_Month_Neuland_Laboratories_Target_Price_for_2027\" title=\"12 Month Neuland Laboratories Target Price for 2027\">12 Month Neuland Laboratories Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Neuland_Laboratories_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Neuland Laboratories Target Price\">How EPS Growth and PE Multiple Change the Neuland Laboratories Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Neuland_Laboratories_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Neuland Laboratories Stock Target in 2027\">Bull Case and Downside Risk for Neuland Laboratories Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Bull_Case_Rs_28063\" title=\"Bull Case Rs 28,063\">Bull Case Rs 28,063<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Downside_Risk_Level_Rs_16811\" title=\"Downside Risk Level Rs 16,811\">Downside Risk Level Rs 16,811<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Key_Risks_to_the_Neuland_Laboratories_Target_Price_for_2027\" title=\"Key Risks to the Neuland Laboratories Target Price for 2027\">Key Risks to the Neuland Laboratories Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Neuland_Laboratories_Price_Target\" title=\"Growth Slowdown Risk for the Neuland Laboratories Price Target\">Growth Slowdown Risk for the Neuland Laboratories Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#How_to_Invest_in_Neuland_Laboratories\" title=\"How to Invest in Neuland Laboratories\">How to Invest in Neuland Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#FAQs_on_Neuland_Laboratories_Share_Price_Target_2027\" title=\"FAQs on Neuland Laboratories Share Price Target 2027\">FAQs on Neuland Laboratories Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_is_the_Neuland_Laboratories_share_price_target_for_2027\" title=\"What is the Neuland Laboratories share price target for 2027?\">What is the Neuland Laboratories share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_is_the_Neuland_Laboratories_share_price_today\" title=\"What is the Neuland Laboratories share price today?\">What is the Neuland Laboratories share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Is_Neuland_Laboratories_a_buy_or_sell_at_the_current_price\" title=\"Is Neuland Laboratories a buy or sell at the current price?\">Is Neuland Laboratories a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Neuland_Laboratories_shares\" title=\"What are the bull case target and downside risk level for Neuland Laboratories shares?\">What are the bull case target and downside risk level for Neuland Laboratories shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_are_the_main_risks_to_the_Neuland_Laboratories_price_target\" title=\"What are the main risks to the Neuland Laboratories price target?\">What are the main risks to the Neuland Laboratories price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_is_the_PE_ratio_of_Neuland_Laboratories_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Neuland Laboratories and how does it compare with the industry?\">What is the PE ratio of Neuland Laboratories and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#Who_owns_Neuland_Laboratories_and_what_is_the_promoter_holding\" title=\"Who owns Neuland Laboratories, and what is the promoter holding?\">Who owns Neuland Laboratories, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/neuland-laboratories-share-price-target-2027\/#What_were_Neuland_Laboratories_latest_quarterly_results\" title=\"What were Neuland Laboratories&#8217; latest quarterly results?\">What were Neuland Laboratories&#8217; latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Neuland Laboratories Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Neuland Laboratories (NSE: NEULANDLAB) has a market capitalisation of Rs 26,961 crore. In FY26 it reported revenue of Rs 2,053 crore and net profit of Rs 364 crore. The table collects the figures the Neuland Laboratories share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/neulandlab\/neuland-laboratories-ltd-share-price-today\">Neuland Laboratories<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>NEULANDLAB<\/td>\n<\/tr>\n<tr>\n<td>CMP (9 October 2026)<\/td>\n<td>Rs 20,890.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 24,225.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 11,500.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 26,961 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>54.16<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>37.59<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>14.39<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>19.42%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.16<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 387.98<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.16%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 23,143<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 28,063<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 16,811<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Neuland_Laboratories_Share_Price_Target_Set_at_Rs_23143_for_2027\"><\/span><strong>Why Is Neuland Laboratories Share Price Target Set at Rs 23,143 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The base-case Neuland Laboratories stock target of Rs 23,143 applies a PE multiple of 54.16 to a forward EPS estimate of Rs 427.31. That EPS assumes 10.1% yearly growth, the pace from FY24 to FY26, and puts the target 10.8% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Neuland_Laboratories_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Neuland Laboratories Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Neuland Laboratories grew revenue from Rs 953.15 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew faster, from Rs 63.82 crore to Rs 364 crore (54.5% a year), which shows margin gains did part of the work and not just higher sales.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>953.15<\/td>\n<td>63.82<\/td>\n<td>49.74<\/td>\n<td>5.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>1,200.95<\/td>\n<td>163.52<\/td>\n<td>127.45<\/td>\n<td>10.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>1,571.12<\/td>\n<td>300.08<\/td>\n<td>233.89<\/td>\n<td>14.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>1,497.35<\/td>\n<td>260.11<\/td>\n<td>202.74<\/td>\n<td>12.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>2,053.15<\/td>\n<td>364.00<\/td>\n<td>283.71<\/td>\n<td>34.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 37.1%, faster than the four-year average of 21.1%, and net profit moved up 39.9%. EPS rose from Rs 233.89 in FY24 to Rs 283.71 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Neuland Laboratories converted 17.7% of FY26 revenue into net profit, against 17.4% in FY25, within a five-year range of 6.7% to 19.1%. EBITDA margin was 29.5% in FY26 versus 28.1% in FY25.<\/p>\n<p>In the June 2026 quarter, revenue was Rs 650.07 crore, up 116.3% from the same quarter a year earlier, while net profit of Rs 147.67 crore was up 962.4%. EBITDA came in at Rs 231.38 crore, up 446.4% year on year. The next quarterly result is the first test of whether the earnings assumption holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.16, and shareholders&#8217; equity grew from Rs 840.50 crore in FY22 to Rs 1,874 crore in FY26. Operating cash flow in FY26 was Rs 346.68 crore against capital expenditure of Rs 397.13 crore, leaving negative free cash flow of Rs 50.45 crore. In FY25 free cash flow was Rs 110.94 crore, so cash generation has not been steady year to year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Neuland_Laboratories_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Neuland Laboratories Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 54.16 against an industry PE of 37.59, Neuland Laboratories trades at a premium to its industry. Price to book is 14.39 on a book value of Rs 1,460.31 per share, and return on equity is 19.42%. A PE of 54.16 equals an earnings yield of 1.8%, and the FY26 dividend of Rs 34.00 per share gives a yield of 0.16%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 32.62% of Neuland Laboratories in June 2026, and promoter holding has stayed near 32.62% since June 2025. Foreign institutional investors (FII) held 21.08% and domestic institutions (DII) held 16.51%, which puts total institutional holding at 37.59%. FII holding fell from 21.69% in June 2025 to 21.08% in June 2026. Public shareholders own the remaining 29.79%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Neuland_Laboratories_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Neuland Laboratories Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Neuland_Laboratories_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Neuland Laboratories Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 20,890.00 on 9 October 2026, Neuland Laboratories trades below its 50-day simple moving average of Rs 22,322.08 and above its 200-day exponential moving average of Rs 18,363.52. The 14-day RSI reads 17.8, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 22,322.08 (50-day simple moving average) and the nearest support is Rs 18,363.52 (200-day exponential moving average). A sustained move above Rs 22,322.08 would improve the short-term setup, while a close below Rs 18,363.52 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Neuland_Laboratories_Target_Price_for_2027\"><\/span><strong>12 Month Neuland Laboratories Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target for Neuland Laboratories is Rs 23,143: forward EPS of Rs 427.31 at a PE of 54.16. That is 10.8% above Rs 20,890.00. It would still leave the stock 4.5% below its 52-week high of Rs 24,225.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Neuland_Laboratories_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Neuland Laboratories Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 43.33<\/th>\n<th>PE 54.16<\/th>\n<th>PE 62.28<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 387.98)<\/td>\n<td>Rs 16,811<\/td>\n<td>Rs 21,013<\/td>\n<td>Rs 24,163<\/td>\n<\/tr>\n<tr>\n<td>10.1% (EPS Rs 427.31)<\/td>\n<td>Rs 18,515<\/td>\n<td>Rs 23,143<\/td>\n<td>Rs 26,613<\/td>\n<\/tr>\n<tr>\n<td>16.1% (EPS Rs 450.59)<\/td>\n<td>Rs 19,524<\/td>\n<td>Rs 24,404<\/td>\n<td>Rs 28,063<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Neuland Laboratories price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Neuland_Laboratories_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Neuland Laboratories Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_28063\"><\/span><strong>Bull Case Rs 28,063<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Neuland Laboratories price target needs EPS growth of 16.1%, which lifts forward EPS to Rs 450.59, and a PE multiple that rises 15% to 62.28. That gives Rs 28,063, 34.3% above the current price and above the 52-week high of Rs 24,225.00, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_16811\"><\/span><strong>Downside Risk Level Rs 16,811<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 387.98 and the PE falls 20% to 43.33. That gives Rs 16,811, 19.5% below the current price and above the 52-week low of Rs 11,500.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>16.1%<\/td>\n<td>62.28<\/td>\n<td>Rs 28,063<\/td>\n<td>+34.3%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>10.1%<\/td>\n<td>54.16<\/td>\n<td>Rs 23,143<\/td>\n<td>+10.8%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>43.33<\/td>\n<td>Rs 16,811<\/td>\n<td>-19.5%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Neuland_Laboratories_Target_Price_for_2027\"><\/span><strong>Key Risks to the Neuland Laboratories Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Neuland_Laboratories_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Neuland Laboratories Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the June 2026 quarter was up 116.3% year on year, and FY26 revenue growth was 37.1%. If growth slows from here, the EPS estimate behind the Neuland Laboratories stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Neuland Laboratories has a market capitalisation of Rs 26,961 crore. Institutional holding is 37.59%, and promoters hold 32.62%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 17.7% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 54.16 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 43.33 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades 13.8% below its 52-week high, with an RSI of 17.8 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Neuland_Laboratories\"><\/span><strong>How to Invest in Neuland Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Neuland Laboratories share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 20,890.00 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Neuland Laboratories&#8217; PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Neuland Laboratories fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Neuland Laboratories target price scenarios with your own view. If you expect EPS growth below 10.1%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Neuland Laboratories live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Neuland Laboratories share price target for 2027 is Rs 23,143 in the base case, with Rs 28,063 as the bull case. The support for that view is arithmetic you can check: EPS grew 10.1% a year over FY24 to FY26, and the stock trades at a PE of 54.16. The risks are equally concrete, including a stock that sits 13.8% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Neuland_Laboratories_Share_Price_Target_2027\"><\/span><strong>FAQs on Neuland Laboratories Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Neuland_Laboratories_share_price_target_for_2027\"><\/span><strong>What is the Neuland Laboratories share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Neuland Laboratories share price target for 2027 is Rs 23,143, with Rs 28,063 as the bull case. The downside risk level, which is not a target, is Rs 16,811. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Neuland_Laboratories_share_price_today\"><\/span><strong>What is the Neuland Laboratories share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 9 October 2026, 3:30 PM IST, Neuland Laboratories trades at Rs 20,890.00, down 0.59% on the day. The 52-week range is Rs 11,500.00 to Rs 24,225.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Neuland_Laboratories_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Neuland Laboratories a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data is mixed rather than one-sided: EPS has grown 10.1% a year over FY24 to FY26, but the stock is 13.8% below its 52-week high. Whether Neuland Laboratories fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Neuland_Laboratories_shares\"><\/span><strong>What are the bull case target and downside risk level for Neuland Laboratories shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case target is Rs 28,063, which assumes 16.1% EPS growth and a PE of 62.28. The downside risk level is Rs 16,811, which assumes flat EPS and a PE of 43.33. It marks a risk, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Neuland_Laboratories_price_target\"><\/span><strong>What are the main risks to the Neuland Laboratories price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are slower revenue growth, a small market capitalisation of Rs 26,961 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Neuland_Laboratories_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Neuland Laboratories and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Neuland Laboratories is 54.16 against an industry PE of 37.59. Price to book is 14.39 and return on equity is 19.42%. The base case in the Neuland Laboratories price target holds this PE constant.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Neuland_Laboratories_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Neuland Laboratories, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 32.62% of Neuland Laboratories in June 2026. FII held 21.08%, DII held 16.51% and the public held 29.79%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Neuland_Laboratories_latest_quarterly_results\"><\/span><strong>What were Neuland Laboratories&#8217; latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the June 2026 quarter, Neuland Laboratories reported revenue of Rs 650.07 crore (up 116.3% year on year) and net profit of Rs 147.67 crore (up 962.4%).<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Neuland Laboratories share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Neuland Laboratories share price target for 2027 is Rs 23,143, with Rs 28,063 as the bull case. The downside risk level, which is not a target, is Rs 16,811. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.\"}},{\"@type\":\"Question\",\"name\":\"What is the Neuland Laboratories share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 9 October 2026, 3:30 PM IST, Neuland Laboratories trades at Rs 20,890.00, down 0.59% on the day. The 52-week range is Rs 11,500.00 to Rs 24,225.00.\"}},{\"@type\":\"Question\",\"name\":\"Is Neuland Laboratories a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data is mixed rather than one-sided: EPS has grown 10.1% a year over FY24 to FY26, but the stock is 13.8% below its 52-week high. Whether Neuland Laboratories fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Neuland Laboratories shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case target is Rs 28,063, which assumes 16.1% EPS growth and a PE of 62.28. The downside risk level is Rs 16,811, which assumes flat EPS and a PE of 43.33. It marks a risk, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Neuland Laboratories price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are slower revenue growth, a small market capitalisation of Rs 26,961 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Neuland Laboratories and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Neuland Laboratories is 54.16 against an industry PE of 37.59. Price to book is 14.39 and return on equity is 19.42%. The base case in the Neuland Laboratories price target holds this PE constant.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Neuland Laboratories, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 32.62% of Neuland Laboratories in June 2026. FII held 21.08%, DII held 16.51% and the public held 29.79%.\"}},{\"@type\":\"Question\",\"name\":\"What were Neuland Laboratories' latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the June 2026 quarter, Neuland Laboratories reported revenue of Rs 650.07 crore (up 116.3% year on year) and net profit of Rs 147.67 crore (up 962.4%).\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neuland Laboratories share price target 2027: base Rs 23,143, bull Rs 28,063, downside risk level Rs 16,811, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":300072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-300073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["300072"],"rank_math_title":["Neuland Laboratories Share Price Target 2027: Base and Bull Case"],"rank_math_description":["The Neuland Laboratories share price target for 2027 is Rs 23,143 versus Rs 20,890.00 today. Bull case, downside risk, earnings trend and risks explained. October 2026."],"rank_math_focus_keyword":["Neuland Laboratories share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/neuland-laboratories-share-price-target-2027-base-and-bull-targets-built-on-fy26.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=300073"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300073\/revisions"}],"predecessor-version":[{"id":300074,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/300073\/revisions\/300074"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/300072"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=300073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=300073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=300073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}